TLR4 and infection: Powdered infant formula supplemented with HMOs protects the colon from infection and reduces the inflammatory response by preventing necrotizing small intestinal colitis (NEC) in mice or piglets and by inhibiting activation of the TLR4 signaling NF-κb signaling pathway (39).